Many markets and niches to get high margin for NPH...Vanc having the whole spectrum of Generics (some low margin and some high margin due to availability), OTC and eventually brand is the key to the power of the business model partially due to the synergies of having a complete offering for the pharmacy channel... I just wanted to mention that Generics are absolutely key in this offering IMO, and also that withing the generics segment I am expecting some that will be much higher margin, than others due to for example being "new generics which have a partial monopoly", or difficult to manufacture generics or other reason which has limited the availability of said generic... NPH management with immense skill in both the pharmacy business in Canada and the international generics business, IMO, is the perfect skill set to have coupled with relationships with many low cost and efficient manuacturing groups, to enable NPH to capitalize on some of these unique generic opportunities that will endlessly come along due to the full pipeline of drugs coming off patent... The pharmacies will all want the commodity generics, and these will pay many bills and nice ROE, but I expect NPH, with its skill will be able to land some sice margin generics... and of course this does not even account for the OTC and future brand licenced prodcuts which will have very large opportunity on their own.... and again IMO the three product segments of the business model are all roughly equally important to the strength of the NPH business model IMO...